What financial metrics can indicate to us that a company is maturing or even in decline? When we see a declining return on capital employed (ROCE) in conjunction with a declining base of capital ...
Healthcare tech company Omnicell (NASDAQ:OMCL) reported Q1 CY2025 results , with sales up 9.6% year on year to $269.7 million. On the other hand, next quarter’s revenue guidance of $275 million was ...
Hosted on MSN
Omnicell (NASDAQ:OMCL) Reports Upbeat Q2, Full-Year Outlook Slightly Exceeds Expectations
Healthcare tech company Omnicell (NASDAQ:OMCL) announced in Q2 CY2025, with sales up 5% year on year to $290.6 million. On top of that, next quarter’s revenue guidance ($295 million at the midpoint) ...
Analysts' ratings for Omnicell (NASDAQ:OMCL) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The following table summarizes their recent ratings, shedding light on the ...
Analysts' ratings for Omnicell (NASDAQ:OMCL) over the last quarter vary from bullish to bearish, as provided by 5 analysts. In the table below, you'll find a summary of their recent ratings, revealing ...
Results exceed previously issued first quarter 2025 guidance for total revenues and non-GAAP EPS Updates full year 2025 non-GAAP EBITDA and non-GAAP EPS guidance FORT WORTH, Texas--(BUSINESS WIRE)-- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback